High Rate of Virological Response to Peginterferon α-2a–Ribavirin Among Non-Cirrhotic Iranian Hemophilia Patients With Chronic Hepatitis C

摘要

BackgroundHepatitis C is a major reason of morbidity and mortality among hemophilia patients. Although combination therapy with peginterferon (peg-INF) and ribavirin is considered as standard treatment for chronic hepatitis C (CHC), but more evidence of the efficacy and safety is needed.